VERTEX PHARMACEUTICALS

Lobbying client · Massachusetts · filed 2025 to 2026

Biopharmaceutical company.

$140,000 Reported spend

6 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 6 filings. Everything on this page is grouped by the client's LDA id (64435), not by name.

Firms hired 1

SALT POINT STRATEGIES $140,000 6 filings

Reported by year 2 years

2026 $10,000 1 filing
2025 $130,000 5 filings

Issues lobbied 1

Pharmacy 6

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 4

HOUSE OF REPRESENTATIVES 5
SENATE 5
Health & Human Services, Dept of (HHS) 2
White House Office 2

Recent filings 6 total

1T

SALT POINT STRATEGIES

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $10,000 income · posted Apr 17, 2026

View → Q4

SALT POINT STRATEGIES

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $40,000 income · posted Jan 18, 2026

View → Q3

SALT POINT STRATEGIES

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $30,000 income · posted Oct 20, 2025

View → Q2

SALT POINT STRATEGIES

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $30,000 income · posted Jul 16, 2025

View → Q1

SALT POINT STRATEGIES

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $30,000 income · posted Apr 19, 2025

View → RR

SALT POINT STRATEGIES

1st Quarter (Jan 1 - Mar 31) 2025 · posted Feb 24, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.